New palladium (II) complexes of thiosemicarbazones: Synthesis, DNA and HSA binding and cytotoxicity activity studies


EĞLENCE BAKIR S., Erdemir E., ŞAHİN M., Špaková I., Smolková R., Smolko L.

Inorganic Chemistry Communications, cilt.179, 2025 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 179
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1016/j.inoche.2025.114783
  • Dergi Adı: Inorganic Chemistry Communications
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Chemical Abstracts Core, Chimica, DIALNET
  • Anahtar Kelimeler: DNA binding, HSA binding, cytotoxicity, Palladium(II), Thiosemicarbazone, X-ray crystallography
  • İstanbul Üniversitesi Adresli: Evet

Özet

Four palladium(II) complexes (I–IV) were synthesized by the reaction of 5-substitute salicylidene (–OCH3, −Br, −Cl, –NO2)-N-isopropyl-S-propyl thiosemicarbazones (LI–IV) with Li2[PdCl4] in ethanol. When 5-OCH3-N-isopropyl-S-propyl thiosemicarbazone (LI) was used as ligand, a [Pd(L)Cl2] complex (complex I) was obtained. In this complex, thiosemicarbazone behaved as bidentate ligand and coordinated to the palladium center with N and S atoms. When other ligands, (−Br, −Cl and –NO2 substituent; respectively LII, LIII and LIV) were used, complexes with the general formula [Pd(L)Cl] and in which thiosemicarbazones behaved tridentate (with O, N and S atoms) were obtained. The ligands and complexes were characterized by using analytical and spectroscopic methods. The molecular structure of complex I was also identified by single crystal X-ray diffraction method which revealed that the Pd(II) central atom was coordinated by thiosemicarbazone ligand through N and S donor atoms and two additional chlorido ligands. All ligands and complexes were subjected to DNA and albumin binding studies, and their antioxidant properties have been evaluated. Complex I and the corresponding ligand LI as the most promising candidates have been selected for the cytotoxicity against the endometrial cancer cell line AN3CA.